ClinicalTrials.gg
CompletedNCT04597983HESPERFORMANUpdated Oct 23, 2020

Effect of 8-week Intake of 2S-hesperidin on Performance, Body Composition and Biochemicals Markers in Amateur Cyclists

An interventional study of 2S-hesperidin and Placebo in Power, Metabolic Disturbance and Change, Body Weight, sponsored by Francisco Javier Martínez Noguera. Completed at 1 site in Spain. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-10-23.

Sponsored by Francisco Javier Martínez Noguera · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years after the study started (first participant enrolled Sep 2018, registered Sep 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Body Weight Changes with a site in Spain — 1 open to participants now, 2 under way, none of them phase 3. Body Weight Changes · Spain.

Enrollment
8th of 10
40 · median 54
Started
2018
with 1 other
No phase
9 of 13
none open now
Registered
7th of 13
by date
Lead sponsor
2 of 13
Francisco Javier Martínez Noguera

Among the 13 studies in Body Weight Changes with a site in Spain, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2018, is one of 9 with no phase, and was the 7th registered.

Body Weight Changes

232 studies on the registry are indexed under Body Weight Changes; 31 are open to participants now.

Browse Body Weight Changes studies →

Open to participants now

1 of the 13 studies in Body Weight Changes with a site in Spain is open now. Recruiting first, the newest first:

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 22 Body Weight Changes studies recruiting now, 9 (41%) set no upper age limit and 12 (55%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Body Weight Changes with a site in Spain, or all of them as a file.
02

Study summary

This clinical study evaluates the effect of 500 mg of 2S-hesperidin for 8 weeks on performance (power generated in different metabolic zones), body composition (fat and muscle mass) and biochemical (antioxidant, inflammatory status) and metabolic (capillary blood in finger) markers in amateur cyclists. Our hypothesis is that chronic intake of 2S-hesperidin can improve performance (maximum power generated). To justify this hypothesis, we measured the parameters mentioned above, which could establish a cause-effect relationship between 2S-hesperidin intake and possible yield improvement.

Read the detailed description

Participants

All participants were informed about the procedures and provided signed informed consent. The study was conducted according to the guidelines of the Helsinki Declaration for Human Research and the protocol was approved by the Ethics Committee/Institutional Review Catholic University of Murcia (Code: CE091802).

Study design

Cyclists were instructed to take the supplement along with breakfast and to continue their usual diet and training schedule. Subjects in both groups were instructed not to consume foods high in citrus flavonoids (grapefruit, lemons or oranges) for 5 days prior to and during the study, this was verified by diet recalls records.

Procedures

Participants visited the laboratory on seven occasions. Visit 1 consisted of a medical examination and blood extraction to determine health status. On visits 2 and 5, a 24-hr diet recall and a Wingate test were performed. On visits 3 and 6, another 24-hour diet recall was conducted, followed by an incremental test until exhaustion on a cycle ergometer. On visits 4 and 7, the 24-hour diet recall was repeated, and participants performed a rectangular test on the cycle ergometer. Prior to each testing session (visits 2, 3, 4, 5, 6 and 7), a standardized breakfast composed of 95.16 g of carbohydrates (68%), 18.86 g of protein (14%) and 11.30 g of lipids (18%) was prescribed by the sport nutritionist.

Pre and post evaluation test

Pre-intervention visits: 1,2,3 and 4 Post-intervention visits: 5,6 and 7

Visit 1:

Health status blood analysis: A general analysis will be performed both in the pre and post-supplementation period. The extraction will be done by venous via. (Fasting)

Medical examination: A clinical history of family and personal history, a resting electrocardiogram (ECG) and a medical examination (auscultation, blood pressure measurement, etc.) will be taken to certify that the person is healthy and not at risk to participate in the study. (Fasting)

Visits 2 and 5:

Resting Metabolic Rate (RMR): A resting test will be performed with the ergospirometer to determine macronutrient supply at rest and caloric expenditure. (Fasting)

Body composition by absorptiometric densitometry (DXA): A body composition test will be performed by the dual energy absorptiometric densitometry technique (X-ray), with the objective of to determine parameters of fat mass, fat-free mass and fat percentage. In addition, anthropometry was also used to determine changes in body composition (fat and muscle mass). (Fasting)

Anaerobic power and mechanical power production: After a standardized breakfast, a Wingate test was performed on a cycloergometer. Wingate test (WAnT) consisted of an all-out 30-s sprint on a cycloergometer (Monark Ergomedic 894E Peak Bike, Vansbro, Sweden). Breaking resistance was held constant at 7.5% of each individual's body mass. All participants were verbally encouraged to pedal as fast as possible during the entire sprint.

Visits 3 and 6:

Incremental step with final ramp test was performed on a cycle ergometer using a metabolic cart (Metalyzer 3B. Leipzig, Germany) to determine maximal fat oxidation zone (FatMax), ventilatory thresholds 1 (VT1) and 2 (VT2) and maximal oxygen consumption (VO2max). Participants began cycling at 35W for 2 min, increasing then by 35W every 2 min until RER>1.05, initialling then the final ramp (+35W·min-1) until exhaustion. The estimated functional threshold power (FTP) was calculated using the following equation [16]:

FTP (W) = Pmax (W) x 0.865 - 56.484.

Visits 4 and 7:

Rectangular test was performed on a cycle ergometer using the power output values resulting from the maximal test (FatMax, VT1 and VT2). Participants exercised continuously from FatMax, to VT1 and to VT2 for 10 min, without rest. Cardiorespiratory variables (VO2, VO2R, carbohydrate oxidation (CHO), fat oxidation (FAT) and cycling economy) were determined for each metabolic zones.

Urine samples

Main hesperidin metabolites were analysed in participants' urine. Urine samples, corresponding to 24 h urine collection from each participant before and after the supplementation, were frozen in liquid nitrogen after collection and thawed for its analysis.

All the data of the subjects who participated in the study were stored under a computer system with a security key. In addition, a record was also made of some of the paper data that was saved under key, and to which only the researchers of this project had access.

03

Conditions studied

  • Power
  • Metabolic Disturbance
  • Change, Body Weight
  • Changes Fatty
  • Muscle Loss
  • Oxidative Stress
  • Inflammatory Response
  • Oxygen Deficiency
  • Acid-Base Imbalance
  • Electrolyte Disturbance

Keywords

  • Flavonoids
  • Polyphenols
  • Power
  • Endurance sports
  • Ergogenic aids
  • Inflammatory markers
  • Antioxidant markers
  • Body Composition
  • Ventilatory Thresholds
  • Nutrigenomic
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-55 years,
  • of 19-25.5 kg·m-2
  • At least 3 years of cycling experience and training for 6-12 h·wk-1

Exclusion criteria

Exclusion Criteria:

  • Were smokers or regular alcohol drinkers,
  • Had a metabolic, cardiorespiratory or digestive pathology or anomaly,
  • Had an injury in the prior 6 months
  • Were supplementing or medicating in the prior 2 weeks
  • Had non-normal values in the blood analysis parameters.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    2S-hesperidin

    This group took 500 mg (capsules) per day at breakfast of 2S-hesperidin (Cardiose®) for 8 weeks

    Dietary Supplement: 2S-hesperidin

  • Placebo comparator
    Placebo

    This group took 500 mg of microcellulose (capsules) per day at breakfast for 8 weeks

    Dietary Supplement: Placebo

Interventions

  • Dietary supplement2S-hesperidin

    Cardiose® is a natural orange extract that due to its unique manufacturing process, maintains most of the natural hesperidin isomeric form (2S)

    Also known as: Cardiose®

  • Dietary supplementPlacebo

    Microcellulose was used, this molecule was selected to avoid affecting the glycemia, as it can occur with dextrose or maltodextrin.

    Also known as: Microcellulose

06

What researchers measure

Primary outcomes

  1. Maximum power

    During the incremental test until exhaustion, the power generated was measured maximum power (W)

    Time frame: Throughout study completion, an average of 8 weeks

  2. Power generated at FatMax

    During the incremental test until exhaustion, the power generated was measured in FatMax (W)

    Time frame: Throughout study completion, an average of 8 weeks

  3. Power generated at ventilatory threshold 1 (VT1)

    During the incremental test until exhaustion, the power generated was measured in VT1 (W)

    Time frame: Throughout study completion, an average of 8 weeks

  4. Power generated at ventilatory threshold 2 (VT2)

    During the incremental test until exhaustion, the power generated was measured in VT2 (W)

    Time frame: Throughout study completion, an average of 8 weeks

Secondary outcomes

  1. Fat mass

    Fat mass (g) was measured by densitometry and anthropometry.

    Time frame: Throughout study completion, an average of 8 weeks

  2. Sum of 8 skinfolds

    By means of anthropometry, the sum of 8 skinfolds (mm) was calculated.

    Time frame: Throughout study completion, an average of 8 weeks

  3. Muscle mass

    Muscle mass (g) was measured by densitometry and anthropometry

    Time frame: Throughout study completion, an average of 8 weeks

  4. Resting metabolic rate

    Resting metabolic rate was measured by indirect calorimetry.

    Time frame: Throughout study completion, an average of 8 weeks

  5. Superoxide dismutase (antioxidant marker)

    During the rectangular test, superoxide dismutase (U/g Hb) was measured in venous blood.

    Time frame: Superoxide dismutase was measured in pre, after the maximum power phase of the rectangular test and after the recovery phase in pre and post intervention (8 weeks) in both groups.

  6. Catalase (antioxidant marker)

    During the rectangular test, catalase (U/g Hb) was measured in venous blood.

    Time frame: Catalase was measured in pre, after the maximum power phase of the rectangular test and after the recovery phase in pre and post intervention (8 weeks) in both groups.

  7. Reduced glutathione (antioxidant marker)

    During the rectangular test, reduced glutathione (GSH) (nmol/mg protein) was measured in venous blood.

    Time frame: Reduced glutathione was measured in pre, after the maximum power phase of the rectangular test and after the recovery phase in pre and post intervention (8 weeks) in both groups.

  8. Oxidized glutathione (antioxidant marker)

    During the rectangular test, oxidized glutathione (GSSG) (nmol/mg protein) was measured in venous blood.

    Time frame: Oxidized glutathione was measured in pre, after the maximum power phase of the rectangular test and after the recovery phase in pre and post intervention (8 weeks) in both groups.

  9. GSSG/GSH ratio (antioxidant marker)

    During the rectangular test, GSSG/GSH ratio (%) was measured in venous blood.

    Time frame: GSSG/GSH ratio was measured in pre, after the maximum power phase of the rectangular test and after the recovery phase in pre and post intervention (8 weeks) in both groups.

  10. Hemoxigenase 1 (antioxidant marker)

    During the rectangular test, hemoxigenase 1 (ng/mL) was measured in venous blood.

    Time frame: Hemoxigenase 1 was measured in pre, after the maximum power phase of the rectangular test and after the recovery phase in pre and post intervention (8 weeks) in both groups.

  11. Thiobarbituric acid reactive substances (oxidant marker)

    During the rectangular test, thiobarbituric acid reactive substances (TBARS) (mcm/L) ( are formed as a byproduct of lipid peroxidation) was measured to determine the oxidative state in venous blood.

    Time frame: Thiobarbituric acid reactive substances was measured in pre, after the maximum power phase of the rectangular test and after the recovery phase in pre and post intervention (8 weeks) in both groups.

  12. Interleukin 6 (inflammatory marker)

    During the rectangular test, interleukin 6 (pg/ml) was measured in venous blood.

    Time frame: Interleukin 6 was measured in pre, after the maximum power phase of the rectangular test and after the recovery phase in pre and post intervention (8 weeks) in both groups.

  13. Tumor necrosis factor (inflammatory marker)

    During the rectangular test, tumor necrosis (pg/ml) was measured in venous blood.

    Time frame: Tumor necrosis factor was measured in pre, after the maximum power phase of the rectangular test and after the recovery phase in pre and post intervention (8 weeks) in both groups.

  14. C-reactive protein (inflammatory marker)

    During the rectangular test, C-reactive protein (mg/L) was measured in venous blood.

    Time frame: C-reactive protein was measured in pre, after the maximum power phase of the rectangular test and after the recovery phase in pre and post intervention (8 weeks) in both groups.

  15. Monocyte chemoattractant protein-1 (inflammatory marker)

    During the rectangular test, monocyte chemoattractant protein-1 (pg/ml) was measured in venous blood.

    Time frame: Monocyte chemoattractant protein-1 was measured in pre, after the maximum power phase of the rectangular test and after the recovery phase in pre and post intervention (8 weeks) in both groups.

  16. Hemoglobin (oximetry marker)

    During the rectangular test, hemoglobin (g/dL) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain)

    Time frame: Hemoglobin was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.)

  17. Hematocrit (oximetry marker)

    During the rectangular test, hematocrit (%) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain)

    Time frame: Hematocrit was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.)

  18. Oxygen saturation (oximetry marker)

    During the rectangular test, oxygen saturation (%) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain)

    Time frame: Oxygen saturation was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.)

  19. Oxygen partial pressure (oximetry marker)

    During the rectangular test, oxygen partial pressure (mmHg) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain)

    Time frame: Oxygen partial pressure was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.)

  20. Carbon dioxide partial pressure (oximetry marker)

    During the rectangular test, carbon dioxide partial pressure (mmHg) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain)

    Time frame: Carbon dioxide partial pressure was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.)

  21. Oxyhemoglobin (oximetry marker)

    During the rectangular test, oxyhemoglobin (%) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain)

    Time frame: Oxyhemoglobin was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.)

  22. Carboxyhemoglobin (oximetry marker)

    During the rectangular test, carboxyhemoglobin (%) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain)

    Time frame: Carboxyhemoglobin was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.)

  23. Deoxyhemoglobin (oximetry marker)

    During the rectangular test, deoxyhemoglobin (%) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain)

    Time frame: Deoxyhemoglobin was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.)

  24. Methemoglobin (oximetry marker)

    During the rectangular test, methemoglobin (%) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain)

    Time frame: Methemoglobin was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.)

  25. Total blood oxygen concentration (oximetry marker)

    During the rectangular test, total blood oxygen concentration (mmol/L) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain)

    Time frame: Total blood oxygen concentration was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.)

  26. Total blood carbon dioxide concentration (oximetry marker)

    During the rectangular test, total blood carbon dioxide concentration (mmol/L) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain)

    Time frame: Total blood carbon dioxide concentration was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.)

  27. Oxygen partial pressure at 50% oxygen saturation (oximetry marker)

    During the rectangular test, oxygen partial pressure at 50% oxygen saturation (mmHg) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain)

    Time frame: Oxygen partial pressure at 50% oxygen saturation was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.)

  28. Relative physiological Shunt (oximetry marker)

    During the rectangular test, relative physiological Shunt (%) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain)

    Time frame: Relative physiological Shunt was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.)

  29. Alveolar-arterial gradient (oximetry marker)

    During the rectangular test, alveolar-arterial gradient (mmHg) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain)

    Time frame: Alveolar-arterial gradient was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.)

  30. Bicarbonate (metabolic marker)

    During the rectangular test, bicarbonate (mmol/L) wasa measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain)

    Time frame: Bicarbonate was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.)

  31. Glucose (metabolic marker)

    During the rectangular test, glucose (mg/dL) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain)

    Time frame: Glucose was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.)

  32. Lactate (metabolic marker)

    During the rectangular test, lactate (mmol/L) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain)

    Time frame: Lactate was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.)

  33. pH (metabolic marker)

    During the rectangular test, pH was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain)

    Time frame: pH was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.)

  34. Actual base excess (metabolic marker)

    During the rectangular test, actual base excess (mmol/L) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain)

    Time frame: Actual base excess was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.)

  35. Standard base excess (metabolic marker)

    During the rectangular test, standard base excess (mmol/L) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain)

    Time frame: Standard base excess was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.)

  36. Sodium (metabolic marker)

    During the rectangular test, sodium (mmol/L) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain)

    Time frame: Sodium was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.)

  37. Potassium (metabolic marker)

    During the rectangular test, potassium (mmol/L) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain)

    Time frame: Potassium was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.)

  38. Chloride (metabolic marker)

    During the rectangular test, chloride (mmol/L) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain)

    Time frame: Chloride was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.)

  39. Calcium (metabolic marker)

    During the rectangular test, calcium (mmol/L) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain)

    Time frame: Calcium was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.)

07

Study locations

1 site
  • Research Center for High Performance Sport. Catholic University of Murcia
    La Ñora, Murcia 30830, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in Dec 2018, 2 months.

Of 90 non-industry interventional studies with no phase under Body Weight Changes, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's 2 months is below that.

Counting every sponsor, half of 99 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2020
First posted
Oct 22, 2020
StartActual
Sep 22, 2018
Primary completionActual
Dec 21, 2018
CompletionActual
Dec 21, 2018
Last update
Oct 23, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04597983
Lead sponsor
Francisco Javier Martínez Noguera
Responsible party
Francisco Javier Martínez Noguera (Research study coordinator, Universidad Católica San Antonio de Murcia) — Sponsor-investigator
First posted
Oct 22, 2020
Start date
Sep 22, 2018
Primary completion
Dec 21, 2018
Completion
Dec 21, 2018
Last update
Oct 23, 2020

Study contacts

Pedro Emilio Alcaraz Ramón
principal investigator · Catholic University of Murcia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion